EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A.
Toosi BM, et al. Among authors: vizeacoumar fj, vizeacoumar fs.
Oncogene. 2018 Jul;37(30):4073-4093. doi: 10.1038/s41388-018-0228-x. Epub 2018 Apr 27.
Oncogene. 2018.
PMID: 29700392
Free PMC article.